Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Lilly's Taltz Positive In Phase III Label Expansion Study

By Zacks Investment ResearchStock MarketsFeb 13, 2018 09:47PM ET
www.investing.com/analysis/lillys-taltz-positive-in-phase-iii-label-expansion-study-200290318
Lilly's Taltz Positive In Phase III Label Expansion Study
By Zacks Investment Research   |  Feb 13, 2018 09:47PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Eli Lilly and Company (NYSE:LLY) announced positive top-line data from a phase III label expansion study evaluating its psoriasis drug, Taltz (ixekizumab), in patients with ankylosing spondylitis (“AS”). The drug met the primary endpoint of improvement in the signs and symptoms of AS and all secondary endpoints as well.

Taltz, an IL-17A antagonist, is currently approved for the treatment of adults with moderate-to-severe plaque psoriasis or active psoriatic arthritis (PsA).

Shares of the company are down 3.3% in the past year, underperforming the industry’s gain of 11.2% in that period.

The phase III study – COAST-V – evaluated the drug in AS patients who have not received any prior treatment with a biologic disease-modifying anti-rheumatic drug. The study consisted of a placebo arm and an active control arm with AbbVie’s (NYSE:ABBV) arthritis drug, Humira. Data from the study showed that treatment with Taltz led to statistically significant improvement as measured by the proportion of patients who achieved Assessment of Spondyloarthritis International Society 40 at 16 weeks.

Additional data from the study is expected to be presented later this year.

Ankylosing spondylitis is a type of spondyloarthritis affecting pelvic joints and spine. It is characterized by chronic inflammatory back pain, stiffness and impaired function and mobility.

Taltz sales increased 14% quarter over quarter in the last quarter of 2017, on the back of strong uptake. In January 2018, the drug received approval in Europe for PsA, which is expected to boost sales of the drug in the first quarter of 2018.

However, several drugs are approved for the treatment of AS including Humira and Novartis’ (NYSE:NVS) Cosentyx. Other companies are developing their therapies for treating AS, which includes Galapagos’ (NASDAQ:GLPG) filgotinib.

Zacks Rank

Lilly carries a Zacks Rank #3 (Hold).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Don’t Even Think About Buying Bitcoin Until You Read This

The most popular cryptocurrency skyrocketed last year, giving some investors the chance to bank 20X returns or even more. Those gains, however, came with serious volatility and risk. Bitcoin sank 25% or more 3 times in 2017.

Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.

See 4 crypto-related stocks now >>



Eli Lilly and Company (LLY): Free Stock Analysis Report

Novartis AG (NVS): Free Stock Analysis Report

AbbVie Inc. (ABBV): Free Stock Analysis Report

Galapagos NV (GLPG): Free Stock Analysis Report

Original post

Zacks Investment Research
Lilly's Taltz Positive In Phase III Label Expansion Study
 

Related Articles

Craig Erlam
A Disappointing End To The Week By Craig Erlam - Jul 30, 2021 2

Stock markets have turned negative on the final trading day of the week, with Europe tracking Asia lower and U.S. markets expected to follow. Whether this is the start of a late...

Lilly's Taltz Positive In Phase III Label Expansion Study

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email